333 related articles for article (PubMed ID: 26743169)
21. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
22. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
[TBL] [Abstract][Full Text] [Related]
23. The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
Srinivasan S; Mir F; Huang JS; Khasawneh FT; Lam SC; Le Breton GC
J Biol Chem; 2009 Jun; 284(24):16108-16117. PubMed ID: 19346255
[TBL] [Abstract][Full Text] [Related]
24. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.
Przyklenk K; Frelinger AL; Linden MD; Whittaker P; Li Y; Barnard MR; Adams J; Morgan M; Al-Shamma H; Michelson AD
J Thromb Haemost; 2010 Feb; 8(2):331-40. PubMed ID: 19922435
[TBL] [Abstract][Full Text] [Related]
25. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
27. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
[TBL] [Abstract][Full Text] [Related]
28. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation.
Chang H; Yanachkov IB; Dix EJ; Li YF; Barnard MR; Wright GE; Michelson AD; Frelinger AL
J Thromb Haemost; 2012 Dec; 10(12):2573-80. PubMed ID: 23083103
[TBL] [Abstract][Full Text] [Related]
29. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2005 May; 93(5):880-8. PubMed ID: 15886804
[TBL] [Abstract][Full Text] [Related]
30. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay.
Li R; Diamond SL
Thromb Res; 2014 Feb; 133(2):203-10. PubMed ID: 24365044
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Storey RF; May JA; Heptinstall S
Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
Yang W; Wang Y; Lai A; Qiao JX; Wang TC; Hua J; Price LA; Shen H; Chen XQ; Wong P; Crain E; Watson C; Huang CS; Seiffert DA; Rehfuss R; Wexler RR; Lam PY
J Med Chem; 2014 Jul; 57(14):6150-64. PubMed ID: 24931384
[TBL] [Abstract][Full Text] [Related]
33. Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target.
Straub A; Krajewski S; Hohmann JD; Westein E; Jia F; Bassler N; Selan C; Kurz J; Wendel HP; Dezfouli S; Yuan Y; Nandurkar H; Jackson S; Hickey MJ; Peter K
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1607-16. PubMed ID: 21512161
[TBL] [Abstract][Full Text] [Related]
34. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
35. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
Savi P; Herbert JM
Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
[TBL] [Abstract][Full Text] [Related]
36. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
[TBL] [Abstract][Full Text] [Related]
37. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
38. Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.
Zhang Y; Ye J; Hu L; Zhang S; Zhang SH; Li Y; Kunapuli SP; Ding Z
J Thromb Haemost; 2012 Oct; 10(10):2149-57. PubMed ID: 22906019
[TBL] [Abstract][Full Text] [Related]
39. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
40. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]